SP . Price movement, page-1377

Further to this, here's an article and quote from DT from BioWorld:

"Although there are numerous tests in the lateral flow class on the market, Anteotech’s COVID-19 ART is differentiated by its speed and overall performance, Thomson said.

“We believe we have a superior test with high sensitivity and specificity based on our unique Anteobind technology,” he said. “The test has an overall sensitivity of 97.3% and a specificity of 99.6%, which puts it in the upper echelon of tests.”

“The COVID-19 ART runs for 14 minutes in a cassette, and the reader is only tied up for a minute, so you could put 60 tests through in an hour for one reader,” he said. “Most readers need to be read immediately, but for ours you can leave it for two hours.”

“The third differentiator is that the test is built on the Eugeni platform that we’ve developed, and we’ve got a number of tests that we can and will bring out on that platform. One is a COVID-19 Flu A/Flu B test that will be out later this year, and then next year we’ll have a test out for sepsis.”

The company is also working on rolling out a new version of the test that works with saliva, and that will be ready to go in about May or June. That means the rapid test will be dual use via either nasopharyngeal or saliva sample.Price points for the test will vary depending on markets, the CEO said. In the U.S. and Europe, it will be priced at about $10 to $12 per test for the COVID-19 ART.

The company is in the process of securing approval from Australia’s Therapeutic Goods Administration (TGA) and hopes to launch the product in Australia in June 2021. It plans on manufacturing the product in Australia."

May and June should REALLY be action packed, with a chance followings to drop at any time (not in particular order) during the next 60 days:

1. Axxin reader contract
2. Operon manufacturing contract
3. UK saliva clinical trials results
4. TGA submission and approval
5. CE approval updated with saliva test ("by June" quoted from quarterly)
6. Results of Indian government discussion
7. Results of Philippines discussion
8. Results from any 1 of the 50 inbound enquiries
9. Asia or Australia manufacturing contract
10. Results from required clinical validation for France, Germany, UK, Italy and Spain
11. Updated Ellume raw material supply contract